Nearly every health plan sold in New York requires prior authorization before it will pay for intravenous immunoglobulin (IVIG). IVIG is a plasma-derived biologic dosed in milligrams per kilogram of body weight, so the cost of a course scales with the patient, and payers review each request against a written policy first.
This article covers what a New York plan asks for, the threshold numbers payers apply, the deadlines New York law imposes, and what to do when a request is denied. For the therapy itself rather than the paperwork, see our IVIG treatment page.
What Is Prior Authorization for IVIG, and Why Does Nearly Every Plan Require It?
Prior authorization is a written approval a health plan issues before it will cover a particular drug for a particular patient. For IVIG it is close to universal. Aetna Clinical Policy Bulletin 0206 on parenteral immunoglobulins, last reviewed June 18, 2026, states that precertification is required for IVIG and for the subcutaneous immunoglobulin products the bulletin lists, and it enumerates 47 covered indications. The same bulletin states that Aetna "considers all other indications as experimental, investigational, or unproven," naming autism spectrum disorder, cystic fibrosis and sarcoidosis among them. An IVIG prior authorization review therefore asks two questions at once: is the diagnosis on the plan's list, and does the chart document the criteria attached to it? Aetna CPB 0206 serves here as a worked example; your own plan publishes its own policy.
What Documentation Does a Payer Require for an IVIG Prior Authorization?
Payers ask for the same core packet almost every time, and requests usually stall on a missing element rather than a wrong diagnosis. The table below combines Aetna CPB 0206 with the CMS Medicare Provider Compliance Tips for intravenous immune globulin. The element missed most often in primary immunodeficiency is the functional antibody test: Aetna CPB 0206 requires documented impaired antibody response to pneumococcal polysaccharide vaccine for all primary antibody deficiencies, so a chart carrying an IgG level but no vaccine-response testing does not meet the criterion. On the Medicare side, CMS names claims lacking a completed Standard Written Order as the most common IVIG denial driver.
| Documentation element | What the payer is checking | Source |
|---|---|---|
| Confirmed diagnosis with ICD-10-CM codes | Codes supporting medical necessity on each claim | CMS MLN |
| Pretreatment quantitative IgG | Age-referenced entry threshold for the specific deficiency | Aetna CPB 0206 |
| Impaired response to pneumococcal polysaccharide vaccine | Required for all primary antibody deficiencies | Aetna CPB 0206 |
| Electrodiagnostic studies | Diagnostic confirmation for CIDP and multifocal motor neuropathy | Aetna CPB 0206 |
| Prior therapies failed, not tolerated, or contraindicated | Step criteria, and wherever a policy says routine use is not indicated | Aetna CPB 0206, CMS MLN |
| Weight in kilograms before each infusion | An accurate weight, since dosing is mg/kg | CMS MLN |
| Physician order not more than 30 days old | Product, dose, rate, frequency and route on a current order | CMS MLN |
| History and physical plus physician rationale | Current within the last 12 months | CMS MLN |
Which IgG Levels and Diagnostic Thresholds Do Payers Apply?
Aetna CPB 0206 sets numeric entry criteria by condition. For severe combined immunodeficiency and agammaglobulinemia the bulletin requires a pretreatment IgG level less than 200 mg/dL. For common variable immunodeficiency (CVID) and hypogammaglobulinemia it requires a pretreatment IgG less than 500 mg/dL or greater than or equal to 2 standard deviations below the mean for age. For chronic inflammatory demyelinating polyneuropathy (CIDP) it requires a course that has been progressive or relapsing and remitting for 2 months or longer, moderate to severe functional disability, and a diagnosis confirmed by electrodiagnostic studies, the workup described in our article on IVIG for CIDP. For refractory myasthenia gravis it requires 2 or more failed standard therapies, and for an acute exacerbation it approves short-term therapy for one month. No FDA-approved immunoglobulin product carries a myasthenia gravis indication, so IVIG in myasthenia gravis is off-label use even where a plan covers it.
How Long Does an IVIG Prior Authorization Decision Take in New York?
New York Insurance Law section 4903 and the parallel Public Health Law provision set the clock. A plan must issue a preauthorization determination "within three business days of receipt of the necessary information." A concurrent review determination, meaning a decision about IVIG already under way, is due within one business day. A retrospective review of care already delivered is due within thirty days. That last phrase is why the documentation packet governs speed: the clock starts when the plan holds what it needs, not when the request was first sent. Section 4903 also limits who may deny. Only a clinical peer reviewer may render an adverse determination; administrative staff are confined to "intake screening, data collection, and non-clinical review functions."
What If Your Plan Requires You to Try a Different Treatment First?
That requirement is step therapy, and New York gives the prescriber a statutory route around it. Under New York Public Health Law section 4903, a plan must grant a step therapy override where the prescriber shows any one of five grounds: the required drug is contraindicated or will likely cause an adverse reaction or physical or mental harm to the enrollee; it is expected to be ineffective based on the known clinical history and conditions of the enrollee; the enrollee tried it and it was discontinued due to lack of efficacy or effectiveness; the enrollee is stable on a prescription drug selected by their health care professional for the condition; or the required drug will likely cause a significant barrier to adherence or compliance with the plan of care. The override determination is due within 72 hours of receipt of the supporting information, and within 24 hours where delay would put the health of the insured in serious jeopardy. An approved override holds for the lesser of the treatment duration indicated by current evidence-based treatment guidelines or twelve months.
How Do You Appeal an IVIG Denial in New York?
New York's external appeal program, created by Chapter 586 of the Laws of New York 1998 and codified in Article 49, sends the dispute to an independent reviewer outside the plan. It covers denials issued on the grounds that a service is not medically necessary or is experimental or investigational, which is how most IVIG denials are written. The filing window is 45 days from the plan's final adverse determination on the first level of internal appeal, or 45 days from receipt of the plan's letter waiving the internal appeal process. External appeals are administered by the New York State Department of Financial Services, not by the health plan. The New York State Department of Health page describing the program does not state the decision timeframe or the filing fee, so neither is quoted here; confirm both with the Department of Financial Services before filing.
What Does a Plan Require to Keep Approving IVIG?
Reauthorization is a separate review, and it is where long-running IVIG is most often interrupted. For immunoglobulin replacement, Aetna CPB 0206 requires a documented reduction in the frequency of bacterial infections since IVIG was started and IgG trough levels monitored at least yearly. For CIDP it requires significant improvement in disability, maintenance of that improvement, and the lowest effective dose and frequency. A trough drawn once at initiation and never repeated will not support continuation, and a dose never revisited invites a reduction at renewal. Prime Infusions administers IVIG on the order the prescribing physician writes, so trough monitoring and periodic dose review belong in the treatment plan from the first cycle.
Where Will Your Plan Approve Your IVIG Infusions?
Site of care is a second authorization decision. UnitedHealthcare's commercial Provider Administered Drugs site-of-care policy, effective August 1, 2026, names intravenous immune globulin and subcutaneous immune globulin explicitly in scope and states that "Alternative Sites of Care, such as non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services are well accepted places of service for medication infusion therapy." Hospital outpatient infusion is approved only on specific criteria, among them medical instability requiring specialized equipment, severe vascular access problems requiring ultrasound guidance, a previous severe adverse event unresponsive to standard interventions, and, for IVIG and SCIG specifically, IgA deficiency with anti-IgA antibodies. Ongoing approval is capped at 6 months. Prime Infusions operates 13 infusion centers across New York, including our Manhattan infusion center on the Upper East Side, our Brooklyn infusion center on Foster Avenue, and our Great Neck infusion center in Nassau County. What the setting does to the bill is covered in our article on IVIG cost in New York.
How Does Prime Infusions Handle Your IVIG Authorization?
Prime Infusions verifies your benefits and submits the prior authorization request together with your prescribing physician, using the documentation set above. Coverage is determined by your health plan, and no infusion provider can promise an approval. What Prime Infusions can do is send the request in complete the first time, with the order inside the 30-day window, the weight in kilograms recorded, and the diagnostic evidence attached. Patients and caregivers can start with the IVIG request form; referring physicians can use our referrals page or call 718-443-4000. Details of the therapy itself are on the IVIG at Prime Infusions page.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. IVIG products carry an FDA boxed warning for thrombosis and for renal dysfunction and acute renal failure; review the full prescribing information for the product prescribed to you and discuss your individual risk factors with your treating clinician. Coverage and out-of-pocket cost are determined by your health plan.